Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q4 FY2021 Earnings Presentation
21 slides from Jubilant Pharmova's earnings presentation, Jun 4, 2021
Slide 1: Financial Results Quarter Ended March 31, 2021
Financial Results Quarter Ended March 31, 2021
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : June 04, 2021 Time : 05:00 pm IST Replay: June 04 to June 10, 2021 Dial-in: +91 22 7194 5757 Playback ID: 40017# 22
Slide 4: Post-Demerger Organisation & Business Structure
Post-Demerger | Organisation & Business Structure Post-Demerger Org Structure Jubilant Life Jubilant Ingrevia Limited Jubilant Pharmova Limited Sciences Limited renamed as Jubilant Pharmova 100% Limited on Feb 1, Carved out Life Science Jubilant Pharma Limited 2021. Company Ingredients business to b
Slide 5: Chairmen's Message
Chairmen’s Message Jubilant Pharmova Q4'FY21 and FY21 performance Continuing Operations Consolidated Results (Continuing Operations + Discontinued Operations) Particulars (Rs Crore) Q4'FY20 Q4'FY21 FY20 FY21 Particulars (Rs Crore) Q4'FY20 Q4'FY21 FY20 FY21 (1 months of LSI) (10 months of LSI) Total
Slide 6: P&L Statement – Continuing and Discontinued Operations
P&L Statement – Continuing and Discontinued Operations Continuing Operations 1 Particulars (Rs Crore) Q4'FY20 Q4'FY21 FY20 FY21 Total Revenue from Operations 1,568 1,580 5,976 6,099 EBITDA 455 381 1,585 1,414 EBITDA margin (%) 29.0% 24.1% 26.5% 23.2% Depreciation 98 86 340 349 Note: Finance Cost 47
Slide 7: Q4'FY21 Results Analysis
Ww) IBILANT Spanien Q4'FY21 Results Analysis
Slide 8: Q4'FY21 Financial Highlights (Continuing Operations)
Q4'FY21 Financial Highlights (Continuing Operations) Particulars1 Q4'FY20 Q4'FY21 YoY (%) LSI business demerged from February 1, 2021 into Jubilant Ingrevia. Continuing Revenue business revenue was Rs 1,580 Crore versus Rs 1,568 Crore in Q4’FY20 Pharmaceuticals 1,483 1,486 0% Contract Research and
Slide 9: Pharmaceuticals Segment Highlights – Q4'FY21 (1/2)
Pharmaceuticals Segment Highlights – Q4'FY21 (1/2) Particulars1 Q4'FY20 Q4'FY21 YoY (%) Pharmaceuticals revenue was at Rs 1,486 Crore vs. Rs 1,483 Crore Revenue 1,483 1,486 0% Specialty Pharma 787 602 (23%) in Q4'FY20 CDMO 388 574 48% Specialty Pharmaceuticals2 Generics 309 309 0% Reported EBITDA
Slide 10: Pharmaceuticals Segment Highlights – Q4'FY21 (2/2)
Pharmaceuticals Segment Highlights – Q4'FY21 (2/2) USFDA Inspection Details CDMO1 Facility Last Inspection • CMO business’ revenue grew YoY based on strong demand from customers as well as COVID related deals Montreal, Radiopharma Sep, 2017 • Spokane site inspected by the US FDA with zero observatio
Slide 11: Contract Research and Development Services – Q4'FY21
Contract Research and Development Services – Q4'FY21 1 Particulars Q4'FY20 Q4'FY21 YoY (%) Revenue 75 94 25% Contract Research and Development Services comprises Reported EBITDA 33 41 25% • Through Jubilant Biosys Limited provides innovative and Reported EBITDA Margin (%) 44.0% 43.7% collaborative
Slide 12: Proprietary Novel Drugs (Jubilant Therapeutics)
Proprietary Novel Drugs (Jubilant Therapeutics) Jubilant Therapeutics is a patient-focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune diseases, with the three lead preclinical first-in-class programs transitioning to clinic over the next 12-18 month
Slide 13: FY21 Results Analysis
WwW) IBILANT Spanien FY21 Results Analysis 12
Slide 14: FY21 Financial Highlights (Continuing Operations)
FY21 Financial Highlights (Continuing Operations) Particulars1 FY20 FY21 YoY (%) Revenue LSI business demerged from February 1, 2021 into Jubilant Ingrevia. Pharmaceuticals 5,714 5,790 1% Contract Research and Development Services 251 305 21% Continuing business revenue was Rs 6,099 Crore versus R
Slide 15: Pharmaceuticals Segment Highlights – FY21
Pharmaceuticals Segment Highlights – FY21 Geography Wise Revenue Particulars1 FY20 FY21 YoY (%) Particulars1 FY20 FY21 YoY (%) Revenue 5,714 5,790 1% India 137 266 95% Specialty Pharma 3,019 2,303 (24%) North America 4,730 4,658 (2%) CDMO 1,536 2,010 31% Europe and Japan 472 439 (7%) Generics 1,159
Slide 16: Contract Research and Development Services – FY21
Contract Research and Development Services – FY21 1 Particulars FY20 FY21 YoY (%) Revenue up 21% YoY to Rs 305 Crore led by higher demand Revenue 251 305 21% Reported EBITDA 85 109 27% from Biotech companies for Integrated Services, DMPK, Reported EBITDA Margin (%) 34.0% 35.6% Biology, and Functio
Slide 17: Debt Profile
Debt Profile Particulars 31-Mar-20 31-Dec-20 31-Mar-21 Jubilant Pharmova (Continuing Business) reduced Foreign Currency Loans (US$ m) (US$ m) (US$ m) its Gross Debt to Rs 2,600 Crore from Rs 3,361 Subsidiaries 431 435 350 Crore as on March 31, 2020 Total 431 435 350 Net Debt (constant currency)
Slide 18: Business outlook
Business outlook Radiopharma: We continue to build a long term pipeline of radiopharmaceuticals including Generics as well as Proprietary products being used as Diagnostic, Therapeutic, Theranostic and Devices, via in-house R&D as well as strategic partnerships with key nuclear medicine companies
Slide 19: Appendix
a Pr ¥ oa (o) VA A p pend IX 18
Slide 20: Income Statement (Continuing Operations) – Q4 & FY21
Income Statement (Continuing Operations) – Q4 & FY21 Particulars1 Q4'FY20 Q4'FY21 YoY (%) FY20 FY21 YoY (%) Revenue Pharmaceuticals 1,483 1,486 0% 5,714 5,790 1% Contract Research and Development Services 75 94 25% 251 305 21% Proprietary Novel Drugs 10 0 10 4 Total Revenue from Continuing Operation
Slide 21: For more information
For more information For Investors: Hemant Bakhru | Pavleen Taneja Siddharth Rangnekar Ph: +91 120 436 1002| 21 CDR India E-mail: hemant.bakhru@jubl.com Ph: +91 22 6645 1209 pavleen.taneja@jubl.com E-mail: siddharth@cdr-india.com For Media: Clayton Dsouza Sudhakar Safaya Madison Public Relations Ph: